Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Price and Financial Metrics


Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)

Today's Latest Price: $120.65 USD

1.23 (-1.01%)

Updated Jun 5 4:00pm

Add JAZZ to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

JAZZ Stock Summary

  • Jazz Pharmaceuticals plc's market capitalization of $6,675,607,813 is ahead of 81.31% of US-listed equities.
  • In terms of twelve month growth in earnings before interest and taxes, Jazz Pharmaceuticals plc is reporting a growth rate of -69.33%; that's higher than only 21.81% of US stocks.
  • In terms of volatility of its share price, JAZZ is more volatile than merely 22.38% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Jazz Pharmaceuticals plc, a group of peers worth examining would be COHR, TRXC, LIVN, CMTL, and SANW.
  • Visit JAZZ's SEC page to see the company's official filings. To visit the company's web site, go to www.jazzpharma.com.
JAZZ Daily Price Range
JAZZ 52-Week Price Range

JAZZ Stock Price Chart More Charts


JAZZ Price/Volume Stats

Current price $120.65 52-week high $154.24
Prev. close $121.88 52-week low $86.88
Day low $120.52 Volume 499,551
Day high $125.00 Avg. volume 610,396
50-day MA $109.71 Dividend yield N/A
200-day MA $127.16 Market Cap 6.68B

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) Company Bio


Jazz Pharmaceuticals is an international biopharmaceutical company with a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. The company was founded in 2003 and is based in Dublin, Ireland.

JAZZ Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$120.65$291.29145%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Jazz Pharmaceuticals plc. To summarize, we found that Jazz Pharmaceuticals plc ranked in the 68th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 146.67% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Jazz Pharmaceuticals plc, consider:

  • Jazz Pharmaceuticals plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 7. This value is greater than only 17.02% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%141%
1%143%
2%145%
3%148%
4%150%
5%153%

NVO, DVA, FTLF, QDEL, and ABBV can be thought of as valuation peers to JAZZ, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


JAZZ Latest News Stream


Event/TimeNews Detail
Loading, please wait...

JAZZ Latest Social Stream


Loading social stream, please wait...

View Full JAZZ Social Stream

Latest JAZZ News From Around the Web

Below are the latest news stories about Jazz Pharmaceuticals plc that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.

Why Is Jazz (JAZZ) Up 4.8% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 4, 2020

Insider Weekends: Activist Investors Add To Their Avid Technology Stake

Insider buying almost doubled last week with insiders purchasing $209.6 million of stock compared to $107.94 million in the week prior. Selling also increased with insiders selling $1.47 billion of stock last week compared to $1.33 billion in the week prior. Sell/Buy Ratio: The insider Sell/Buy ratio is calculated by...

Asif Suria | June 1, 2020

Top Insider Buys Highlight for the Week of May 29

Insiders loaded up on TJX Companies, Boston Properties, Royal Caribbean Cruises and Jazz Pharmaceuticals Continue reading...

Yahoo | May 30, 2020

Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:

Yahoo | May 27, 2020

Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from May 29-June 2, 2020 and six abstracts at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. These new data from Jazz's expanding hematology and oncology portfolio and pipeline are focused on difficult-to-treat cancers, or related disorders, which have few, if any, treatment options.

Yahoo | May 14, 2020

Read More 'JAZZ' Stories Here

JAZZ Price Returns

1-mo 10.23%
3-mo 0.76%
6-mo -20.28%
1-year -7.88%
3-year -20.43%
5-year -30.77%
YTD -19.18%
2019 20.43%
2018 -7.94%
2017 23.50%
2016 -22.43%
2015 -14.15%

Continue Researching JAZZ

Here are a few links from around the web to help you further your research on Jazz Pharmaceuticals plc's stock as an investment opportunity:

Jazz Pharmaceuticals plc (JAZZ) Stock Price | Nasdaq
Jazz Pharmaceuticals plc (JAZZ) Stock Quote, History and News - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8634 seconds.